Scarica l'app Stockscreener
29.00
2.62%
-0.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Genmab Adr Borsa (GMAB) Ultime notizie
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewswire Inc.
GMABGenmab ADR Earnings - Finviz
Amazon To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Sahm
Genmab (GMAB) Shows Modest Gains Amid Consolidation: Support and Resistance Levels in FocusSector Neutral Pair - dars.gov.et
Genmab A/S Sponsored ADR Actuals & Estimates (NASDAQ:GMAB) - TradingView
GE91 Forecast — Price Target — Prediction for 2027 - TradingView
GMAB1/N Forecast — Price Target — Prediction for 2027 - TradingView
GMAB News | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab A/S stock (DK0010272202): Copenhagen shares weaken as investors weigh outlook after updated A - AD HOC NEWS
GMAB Q1 2026 Earnings: EPS Misses Estimates by Over 40% as Stock DeclinesQuarterly Earnings Report - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
GMAB Stock Price, Quote & Chart | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
GMAB vs. ACAD: Which Stock Is the Better Value Option? - MSN
Genmab A/S stock (DK0010272202): earnings momentum and oncology pipeline keep investors watching - AD HOC NEWS
Genmab stock (DK0010272202): Analyst sentiment shifts as earnings forecasts decline - AD HOC NEWS
Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook - Morningstar
Genmab A/S Q1 Earnings Call Highlights - Yahoo Finance
Oppenheimer Asset Management Inc. Acquires 48,894 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Pictet Asset Management Holding SA Takes $33.84 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR shows improved relative strength; still shy of benchmark - MSN
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - GlobeNewswire Inc.
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Genmab A/S (NASDAQ:GMAB) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by Assetmark Inc. - MarketBeat
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Sahm
827,217 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Perpetual Ltd - marketbeat.com
JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab AS (ADR) (US3723032062.SG) Q1 FY2025 earnings call transcript - Yahoo Finance
Terra Nova Asset Management LLC Invests $1.87 Million in Genmab A/S Sponsored ADR $GMAB - MarketBeat
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches - Yahoo Finance
Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Genmab A/ S: The Biotech Stock Gen Z Is Quietly Watching - AD HOC NEWS
Russell Investments Group Ltd. Has $25.23 Million Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
GMAB Earnings History & Surprises | EPS & Revenue Results | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case - ChartMill
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):